What we’re looking for
The Psychiatry Consortium is seeking project proposals which focus on the validation of novel molecular drug-targets for the following mental health conditions:
psychotic disorders, bipolar disorder, depression, anxiety, stress-related disorders, PTSD, OCD, autism spectrum disorders as well as psychiatric symptoms associated with dementia and other cognitive disorders
The Psychiatry Consortium intend to fund projects which:
- show some evidence that links the molecular target to human disease and of the target modulation having a therapeutic effect, which can be further developed or validated
- will enable tools for target validation e.g. through optimisation of existing tool compounds to improve selectivity, potency, bioavailability
Projects seeking to identify target modulation biomarkers relevant to disease will also be in scope.
For help determining whether your project is in scope, see our Resources, or if you are interested to find out more about the scope of the call and the funding model, you can watch our latest webinar or contact the Programme Manager.